Register
Login:
Share:
Email Facebook Twitter


ETF Investing made simple; CEO of justETF explains why


Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 190.00Bid: 185.00Ask: 195.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 10.00Spread as %: 5.41%Open: 190.00High: 190.00Low: 190.00Yesterday’s Close: 190.00

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
190.00

Share Price SpacerBid
185.00

Share Price SpacerAsk
195.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
0

Share Price SpacerOpen
190.00

Share Price SpacerHigh
190.00

Share Price SpacerLow
190.00

Share Price SpacerClose
190.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 61.84m £117.50m 2,000

52 Week High 260.00 52 Week High Date 4-OCT-2016
52 Week Low 82.50 52 Week Low Date 4-MAR-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
0 0 0 -6.552 -29.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

21-Feb-17
16:26:40
192.00
15,000
Buy* 
185.00
195.00
28.80k
Trade Type:
Ordinary

21-Feb-17
16:17:26
188.61
1,000
Sell* 
185.00
195.00
1,886
Trade Type:
Ordinary

21-Feb-17
16:13:14
188.65
2,000
Sell* 
185.00
195.00
3,773
Trade Type:
Ordinary




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Tue 13:28Free-MoneyRE: RPDPR Voucher190.00No Opinion
Thanks, that should help make sure they have the funds to pay Summit's milestones.... first one being $22m on 1st April if they dose the last patient in the PhaseOut study by then.

It's is also good to note that Summit should be able to achieve $125m for their voucher on approval of Ezuromid (maybe in 2019 under the current plan). Although if Ezutromid is approved, $125m extra will be small change!!!

We also know that we will not need the voucher for Ridinilazole since that drugs already… Read More
Tue 13:12gmccRE: RPDPR Voucher190.00No Opinion
Tue 13:08gmccRPDPR Voucher190.00No Opinion
Think SUMM have a RPDPR Voucher ; Note Sarepta just sold theirs !

" Sarepta Therapeutics (NASDAQ:SRPT) perks up 2% premarket on light volume in response to its announcement that it has inked an agreement with an unnamed party to sell its Rare Pediatric Disease Priority Review Voucher for $125M. It received the voucher from the FDA when it approved EXONDYS 51.

The sale price appears modest considering that AbbVie bought one for $350M from United Therapeutics in… Read More
Thu 20:21OddmoneyPoint72 Asset Management, L.P.190.00Strong Buy
Point72 Asset Management, L.P. bought 4.6million shares. - the form SC 13 G/A was filed on 14.2.2017, yet the document states that the Event Date was 31.12.2016. can anyone explain the delay or were we notified of this and I missed it?
Thu 14:08Free-MoneySarepta - target $76190.00No Opinion
https://www.smarteranalyst.com/2017/02/16/oppenheimer-stays-bullish-sarepta-therapeutics-inc-srpt-stock-shows-signs-weakness/

Singh noted, “The current $1.5B market cap indicates that the Street values peak Exondys 51 sales in the US at $300M to $500M (at 3x to 5x future sales). This is at the low end of biotech growth story multiples, and increasing visibility on the continuing successful US launch could lead to a multiple expansion up to twice that is currently… Read More
Thu 11:16wildbunchmoney for CEO190.00No Opinion
We may be happy to wait for returns-CEO probably would like to trouser £2m+ if he could get to to £6 sharpish. The only way to do this is to have great deal for C diff soon.

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.